AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33243030
Drug: Metformin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin treatment (2 g/day)
Trial: 34364737
Drug: Mulabandha yoga
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mulabandha yoga therapy (MYT) for 12 weeks
Trial: 35123664
Drug: Probiotic and
RxNorm normalized name: Florastor Advanced Probiotic And Digestive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic and peanut oral immunotherapy (PPOIT)
Trial: 32311780
Drug: Lipegfilgrastim (LIPEG)
DrugBank: Lipegfilgrastim (DB13200)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Lipegfilgrastim (LIPEG) 6 mg
Trial: 33345452
Drug: SGLT2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitors (75% adoption)
Trial: 32534376
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (30 mg elemental zinc)
Trial: 32961802
Drug: SVF injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SVF injection
Trial: 35112890
Drug: ivabradine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine (5 mg BID, 1-week)
Trial: 33269798
Drug: Sinovac EV71
RxNorm normalized name: COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinovac EV71 vaccine
Trial: 33271095
Drug: Gemogenovatucel-T (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemogenovatucel-T (1 × 10^7 cells per injection), administered intradermally (one per month) for a minimum of four and up to 12 doses.
Trial: 33271095
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered intradermally (one per month) for a minimum of four and up to 12 doses.
Trial: 33713335
Drug: Self-esteem group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-esteem group with treatment as usual (TAU)
Trial: 33094848
Drug: Home enteral
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home enteral and parenteral nutrition support
Trial: 34092255
Drug: Topical high-linoleate
RxNorm normalized name: linoleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical high-linoleate sunflower seed oil (SSO) applied at 3 g/kg three times daily for 10 days
Trial: 34092255
Drug: Topical high-linoleate
RxNorm normalized name: linoleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical high-linoleate sunflower seed oil (SSO)
Trial: 34663681
Drug: 3-minute high-intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-minute high-intensity interval exercise program (jumps, squats, various steps) implemented twice weekly over 10 weeks for 10 to 25 minutes per session
Trial: 34482350
Drug: F/TAF 200 mg/25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F/TAF 200 mg/25 mg
Trial: 34482350
Drug: F/TDF 200 mg/300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F/TDF 200 mg/300 mg
Trial: 32089078
Drug: 12-session weekly
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-session weekly yoga intervention
Trial: 33287836
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment in PCOS patients (PCOS-GH)
Trial: 36263739
Drug: Osmotic-release oral
RxNorm normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Osmotic-release oral system methylphenidate (OROS-methylphenidate)
Trial: 35948418
Drug: OPEP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPEP therapy using Acapella device for 3 months
Trial: 34936265
Drug: Suspension training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension training
Trial: 35623878
Drug: Intravenous 2
RxNorm normalized name: Premarin Intravenous 25 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 2 g of vitamin C in normal saline
Trial: 35623878
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline therapy (control)
Trial: 34503460
Drug: Skull remodeling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skull remodeling surgery, Tumor Treating Fields therapy (TTFields), and best practice oncology
Trial: 34503460
Drug: Tumor Treating
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor Treating Fields therapy (TTFields) and best physicians choice oncological treatment (control arm)
Trial: 32618829
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (MgSO4) 300 mg daily for 6 months
Trial: 35871083
Drug: Low-dose Neu2000K
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Neu2000K
Trial: 35871083
Drug: High-dose Neu2000K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Neu2000K
Trial: 32682962
Drug: Guideline directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline directed medical therapy (GDMT)
Trial: 36210809
Drug: Mesalazine (4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine (4.0 g/d, once a day for 3 months)
Trial: 33945920
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care (PC) group
Trial: 34481420
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (PBM) combined with standard skincare (2x/week) during the complete radiotherapy course
Trial: 34184795
Drug: On-line self-help
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-line self-help intervention consisting of 10 modules based on cognitive-behavioral therapy and motivational interviewing.
Trial: 36342972
Drug: DPP-4 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DPP-4 inhibitors
Trial: 39608381
Drug: GLP-1 receptor
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 receptor agonists
Trial: 32664094
Drug: Intravenous normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous normal saline (control group)
Trial: 33063610
Drug: Histamine H3
RxNorm normalized name: Histamine H3 receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine H3 receptor gene variant (rs13042865)
Trial: 34248041
Drug: Standard dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosage of terlipressin
Trial: 34248041
Drug: Modified dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified dose of terlipressin
Trial: 38250270
Drug: Mindfulness Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness Based Cognitive Therapy (MBCT)
Trial: 39055495
Drug: Capecitabine monotherapy
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine monotherapy
Trial: 34616489
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg plus best supportive care (BSC)
Trial: 35771645
Drug: Taper period
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taper period after intensified training
Trial: 34497078
Drug: Adjunctive use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive use of an internet-based self-management intervention (priovi)
Trial: 35267951
Drug: Behavioral weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral weight loss (BWL) treatment for 4 months
Trial: 37344262
Drug: PCV13 (13-valent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV13 (13-valent pneumococcal conjugate vaccine)
Trial: 35146039
Drug: PPSV23 (23-valent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPSV23 (23-valent pneumococcal polysaccharide vaccine)
Trial: 37021410
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ezetimibe (EZE) tablets (test product)
Trial: 37021410
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ezetimibe (EZE) tablets (reference product)
Trial: 35695720
Drug: Paliperidone ER
RxNorm normalized name: Paliperidone ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paliperidone ER (6-15 mg/d)
Trial: 35695720
Drug: Olanzapine (10-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (10-30 mg/d)
Trial: 34023351
Drug: Glecaprevir/pibrentasvir (G/P)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glecaprevir/pibrentasvir (G/P) for 12 or 16 weeks
Trial: 34023351
Drug: Glecaprevir/pibrentasvir (G/P)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glecaprevir/pibrentasvir (G/P) with ribavirin for 12 weeks
Trial: 34023351
Drug: Treatment-emergent NS5A
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-emergent NS5A RASs
Trial: 34930979
Drug: Tenoten (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoten (8 tablets/day)
Trial: 35947279
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of BFT and dapoxetine 30 mg
Trial: 33536096
Drug: Oily fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oily fish consumption (about 300 g/week for 12 weeks)
Trial: 32638463
Drug: Intralesional injection
RxNorm normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of botulinum toxin type A once a month for 4 months
Trial: 34404237
Drug: Clopidogrel-monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel-monotherapy
Trial: 34404237
Drug: DAPT using
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPT using cilostazol and aspirin
Trial: 33119477
Drug: Control group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: pelvic radiation of 50 Gy/25 fractions with concurrent capecitabine, followed by oxaliplatin and capecitabine
Trial: 35876837
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy (BLT) for 30 minutes in the morning at 10,000 lux for 6 weeks
Trial: 38195732
Drug: Non-surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical periodontal therapy (NSPT)
Trial: 35184691
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose intravenous cefuroxime after cord clamping (n=19)
Trial: 35184691
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose intravenous cefuroxime 30 minutes before skin incision (n=21)
Trial: 35811518
Drug: Personalized, precision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized, precision medicine protocol for nine months
Trial: 34391239
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (non-therapeutic gel with light touch for 3min)
Trial: 33532013
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg amitriptyline at bedtime
Trial: 33722585
Drug: Quadrivalent high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent high-dose influenza vaccine (QIV-HD)
Trial: 39303788
Drug: Standard-dose quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose quadrivalent influenza vaccine (QIV-SD)
Trial: 36181316
Drug: PegIFN‐α monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFN‐α monotherapy (180 μg/week)
Trial: 33633016
Drug: 1% Phentolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% Phentolamine mesylate ophthalmic solution (PMOS)
Trial: 33633016
Drug: 1% Phentolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% Phentolamine mesylate ophthalmic solution (PMOS) in the tropicamide subgroup
Trial: 34726625
Drug: Immediate neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate neoadjuvant instillation of chemotherapy (INAIC) with mitomycin C before TURBT (Group A)
Trial: 32366224
Drug: Lidocaine/prilocaine cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine/prilocaine cream (2 g applied to the tracheal tube cuff)
Trial: 32366224
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Vaseline 2 g applied to the tracheal tube cuff)
Trial: 37041561
Drug: EIT-guided PEEP
RxNorm normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EIT-guided PEEP titration
Trial: 35887937
Drug: Intensive periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive periodontal treatment
Trial: 32795875
Drug: 70-gene signature
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 70-gene signature (MammaPrint®) guided treatment strategy
Trial: 34709369
Drug: Low-dose CT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CT of the chest
Trial: 32486583
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of levosimendan (0.1 μg·kg(‐1)·min(‐1) for 24 h after loading with 6 μg/kg)
Trial: 32486583
Drug: Maintenance dose
RxNorm normalized name: Firmagon 80mg Powder for Injection Maintenance Dose Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance dose of levosimendan (same schedule without loading dose)
Trial: 35869311
Drug: Concentrated beetroot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated beetroot juice (BJ) 24 ml daily for 12 weeks
Trial: 35109906
Drug: Topical fusidic
RxNorm normalized name: fusidate Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fusidic acid
Trial: 34288591
Drug: Home infusions
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home infusions of natalizumab (n=18)
Trial: 32781869
Drug: sl‐wIRAR treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sl‐wIRAR treatment (2 treatments for 30 min per day for 6 days)
Trial: 34602460
Drug: sl‐wIRAR treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sl‐wIRAR treatment
Trial: 32781869
Drug: NSAID therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID therapy reduction
Trial: 38315944
Drug: Physician's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's choice chemotherapy
Trial: 39665235
Drug: Pindolol 30
RxNorm normalized name: Pindolol
DrugBank: Pindolol (DB00960)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pindolol 30 mg
Trial: 33021110
Drug: Zonisamide as
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zonisamide as an adjunctive treatment to levodopa
Trial: 37115133
Drug: Polypharmacy (≥5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypharmacy (≥5 medications excluding HFrEF GDMT) at baseline
Trial: 37115133
Drug: No polypharmacy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No polypharmacy (<5 medications) at baseline
Trial: 36088609
Drug: Luminor® 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luminor® 35 drug‐coated balloon (DCB) angioplasty
Trial: 32584155
Drug: AKL-T03 (videogame-like
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKL-T03 (videogame-like digital treatment)
Trial: 34223734
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg Genistein (GEN)
Trial: 33713484
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline injection
Trial: 36584579
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline injection
Trial: 32749733
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy only (Control)
Trial: 36308446
Drug: Anticoagulated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulated group (warfarin + aspirin)
Trial: 36308446
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (aspirin only)
Trial: 34597899
Drug: Sepranolone 10
RxNorm normalized name: Sepranolone
DrugBank: Sepranolone (DB12972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sepranolone 10 mg
Trial: 34597899
Drug: Sepranolone 16
RxNorm normalized name: Sepranolone
DrugBank: Sepranolone (DB12972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sepranolone 16 mg
Trial: 32464527
Drug: CLIP intervention
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CLIP intervention (community engagement, community health worker-provided mobile health-guided clinical assessment, initial treatment, and referral)
Trial: 35468266
Drug: Group-based outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based outpatient physical therapy delivered 6 weeks after TKR, costing £179 ± 39 per patient.
Trial: 35189843
Drug: Tablet-based video
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based video intervention about IPV and safety behaviours
Trial: 35667527
Drug: Stereotactic ablative
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic ablative radiotherapy (SABR) planned for 332 lesions in 296 separate PTVs, with common prescriptions of 30-35 Gy in 5 fractions (43% of lesions) and 20-24 Gy in 1 fraction (33% of lesions).
Trial: 33528816
Drug: Multi-period design
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-period design with varying weekly measurement schemes
Trial: 33908117
Drug: Placebo (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.2 mL of placebo)
Trial: 33691699
Drug: Stepwise CMD
RxNorm normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Stepwise CMD risk assessment and individualized treatment
Trial: 34273987
Drug: Intravenous LPS
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous LPS (Escherichia coli O113, 2 ng/kg)
Trial: 36469573
Drug: Neoadjuvant durvalumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant durvalumab plus tremelimumab (combination therapy)
Trial: 34118298
Drug: Delgocitinib 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delgocitinib 0.25% ointment
Trial: 34118298
Drug: Delgocitinib 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delgocitinib 0.25% or 0.5% ointment (Part 2)
Trial: 32947424
Drug: Pregnenolone adjunct
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnenolone adjunct to risperidone
Trial: 32947424
Drug: Placebo adjunct
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo adjunct to risperidone
Trial: 35346889
Drug: Maternal glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal glycemic control (fasting and 1-hour postprandial or serial intrapartum capillary blood glucose screening with insulin treatment as indicated)
Trial: 33741732
Drug: Camrelizumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab (3 mg/kg, once every 2 weeks) plus apatinib (500 mg, once per day)
Trial: 33359589
Drug: Daily dosing
RxNorm normalized name: Osmolex 322 MG Daily Dosing Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dosing of PTAH (cohorts 1 and 3A)
Trial: 32987448
Drug: Mupirocin ointment
RxNorm normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mupirocin ointment
Trial: 33495008
Drug: GH 4
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 3 MCG/0.2 ML Injectable Suspension, 6m through 4y (EUA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH 4 IU/day subcutaneous injection
Trial: 34602396
Drug: Intravenous anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anesthesia with dexmedetomidine and propofol combined with seaweed polysaccharides
Trial: 34602396
Drug: Intravenous anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anesthesia with sufentanil combined with propofol
Trial: 34958402
Drug: Medication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication therapy for osteoporosis
Trial: 33198942
Drug: Passive Scattering
RxNorm normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive Scattering Proton Therapy (PSPT)
Trial: 34259871
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of smoking cessation medication